In addition to frequent c-KIT activation, genomic aberrations in CDK4 pathway related genes, such as CDK4, CCND1, and CDKN2A, have been identified in more than 80% of AM patients (Kong et al., 2017), and CDK4/6i monotherapy had a favorable safety profile in a small phase II clinical trial (Mao et al., 2021). This evidence concerns the gene CDK4 and acute myeloblastic leukemia with maturation.